STOCK TITAN
  1. Home
  2. Financials
  3. PMN

Promis Neuroscie Financials

PMN
Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Promis Neuroscie (PMN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PMN FY2025

ProMIS is operating like a cash-funded research platform, with development spending rather than commercial revenue driving the balance sheet.

Across recent annual filings, financing inflows of $66.6M roughly matched cumulative operating cash burn of $66.1M, which means the business has effectively been sustained by new capital rather than internally generated cash.

The latest deterioration came mainly from R&D intensity: research spending jumped to $33.4M from $10.6M, while SG&A stayed in the same general range. Because revenue is absent, that spend behaves more like program investment than the cost of supporting sales, so reported losses mostly reflect how aggressively the pipeline is being funded.

The one year of positive net income at $2.8M did not reflect cash economics, because operating cash flow was still -$27.2M. In the latest year, liquidity had tightened to a 0.9x current ratio and cash of $6.1M, so the balance sheet no longer provided the cushion visible earlier. The business also moved back to negative equity, showing how quickly a financing buffer can disappear when cash burn persists.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 19 / 100
Financial Profile 19/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Promis Neuroscie's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage
99

Promis Neuroscie carries a low D/E ratio of -8.30, meaning only $-8.30 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
12

Promis Neuroscie's current ratio of 0.88 is below the typical benchmark, resulting in a score of 12/100. However, the company holds substantial cash reserves (59% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Piotroski F-Score Weak
1/9

Promis Neuroscie passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality
0.71x

For every $1 of reported earnings, Promis Neuroscie generates $0.71 in operating cash flow (-$28.1M OCF vs -$39.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
N/A
Net Income
-$39.7M
YoY-1529.3%

Promis Neuroscie reported -$39.7M in net income in fiscal year 2025. This represents a decrease of 1529.3% from the prior year.

EPS (Diluted)
$-22.61
YoY-959.7%

Promis Neuroscie earned $-22.61 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 959.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$6.1M
YoY-54.0%

Promis Neuroscie held $6.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
2M
YoY+64.6%

Promis Neuroscie had 2M shares outstanding in fiscal year 2025. This represents an increase of 64.6% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
$33.4M
YoY+213.8%

Promis Neuroscie invested $33.4M in research and development in fiscal year 2025. This represents an increase of 213.8% from the prior year.

Share Buybacks
N/A
Capital Expenditures
N/A

PMN Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses $7.0M N/A $9.8M+12.0% $8.7M+60.1% $5.5M N/A $2.6M+57.7% $1.6M
SG&A Expenses $1.7M N/A $2.0M+36.1% $1.4M-28.1% $2.0M N/A $1.9M+72.0% $1.1M
Operating Income -$8.6M N/A -$11.8M-15.4% -$10.2M-36.5% -$7.5M N/A -$4.4M-63.4% -$2.7M
Interest Expense N/A N/A N/A N/A N/A N/A N/A N/A
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income -$8.2M N/A -$11.6M-14.5% -$10.1M-37.7% -$7.3M N/A $9.3M+453.5% -$2.6M
EPS (Diluted) $-1.26 N/A $-0.24+17.2% $-0.29+94.5% $-5.27 N/A $0.31+338.5% $-0.13

PMN Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $67.4M+634.1% $9.2M-57.2% $21.5M+125.6% $9.5M-30.3% $13.6M-27.8% $18.9M-22.8% $24.5M+1638.8% $1.4M
Current Assets $65.6M+614.5% $9.2M-57.2% $21.5M+125.6% $9.5M-30.3% $13.6M-27.8% $18.9M-22.8% $24.5M+1638.8% $1.4M
Cash & Equivalents $63.8M+943.3% $6.1M-60.3% $15.4M+241.4% $4.5M-46.1% $8.4M-37.1% $13.3M-38.3% $21.5M+2070.0% $992K
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $6.7M-35.9% $10.4M-14.9% $12.3M+24.0% $9.9M+136.9% $4.2M+72.3% $2.4M-85.9% $17.2M+367.6% $3.7M
Current Liabilities $6.6M-36.5% $10.4M-14.7% $12.2M+24.3% $9.8M+142.2% $4.1M+82.8% $2.2M-15.8% $2.6M-16.9% $3.2M
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity $60.7M+4924.2% -$1.3M-113.7% $9.2M+2501.4% -$383K-104.0% $9.5M-42.6% $16.5M+126.7% $7.3M+419.4% -$2.3M
Retained Earnings -$138.7M-6.3% -$130.4M-8.9% -$119.7M-10.7% -$108.2M-10.3% -$98.0M-8.1% -$90.7M-0.3% -$90.4M+9.3% -$99.7M

PMN Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow -$12.4M-33.4% -$9.3M+7.7% -$10.1M-160.9% -$3.9M+21.8% -$4.9M+43.5% -$8.7M-30.6% -$6.7M-343.4% -$1.5M
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow $70.1M+7008131000.0% -$1 N/A N/A N/A $470K-98.3% $27.2M $0
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

PMN Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity -13.6% N/A -126.0% N/A -77.6% N/A 127.5% N/A
Return on Assets -12.2% N/A -54.0%+52.4pp -106.4%-52.6pp -53.8% N/A 37.8%+224.0pp -186.1%
Current Ratio 9.92+9.0 0.88-0.9 1.76+0.8 0.97-2.4 3.36-5.2 8.52-0.8 9.30+8.9 0.44
Debt-to-Equity 0.11+8.4 -8.30-9.6 1.34+27.2 -25.86-26.3 0.44+0.3 0.15-2.2 2.37+4.0 -1.62
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.88), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Q32 BIO INC QTTB
$96.1M
Curis CRIS
$19.3M
Elevation Oncolo ELEV
$21.6M
Lisata Therapeutics Inc LSTA
$29.0M
Akari Therapeutics Plc AKTX
$3.9M

Frequently Asked Questions

No, Promis Neuroscie (PMN) reported a net income of -$39.7M in fiscal year 2025.

Promis Neuroscie (PMN) reported diluted earnings per share of $-22.61 for fiscal year 2025. This represents a -959.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Promis Neuroscie (PMN) generated -$28.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Promis Neuroscie (PMN) had $9.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Promis Neuroscie (PMN) invested $33.4M in research and development during fiscal year 2025.

Promis Neuroscie (PMN) had 2M shares outstanding as of fiscal year 2025.

Promis Neuroscie (PMN) had a current ratio of 0.88 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Promis Neuroscie (PMN) had a debt-to-equity ratio of -8.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Promis Neuroscie (PMN) had a return on assets of -432.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Promis Neuroscie (PMN) had $6.1M in cash against an annual operating cash burn of $28.1M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Promis Neuroscie (PMN) has negative shareholder equity of -$1.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Promis Neuroscie (PMN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Promis Neuroscie (PMN) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Promis Neuroscie (PMN) scores 19 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top